Mild Cognitive Impairment  >>  elenbecestat (E2609)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
elenbecestat (E2609) / Eisai, Biogen
NCT01600859: Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

Checkmark For mild cognitive impairment or mild dementia due to Alzheimer's disease
Nov 2013 - Nov 2013: For mild cognitive impairment or mild dementia due to Alzheimer's disease
Completed
1
65
US
E2609, Placebo for E2609
Eisai Inc.
Alzheimer's Disease
09/13
10/13

Download Options